Yıl: 2021 Cilt: 38 Sayı: 1 Sayfa Aralığı: 33 - 40 Metin Dili: İngilizce DOI: 10.4274/tjh.galenos.2020.2020.0115 İndeks Tarihi: 31-01-2022

Evaluation of Prognostic Significance of the International Staging System According to Glomerular Filtration Rate in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation

Öz:
Objective: The prognosis of multiple myeloma (MM) patients is highly heterogeneous. The aim of this study is to determine the impact of patients’ renal functions on the prognostic performance of the International Staging System (ISS). In addition, we aimed to evaluate the results of survival of patients with ISS stages and normal renal functions and those with ISS stages and abnormal renal functions with this study. Materials and Methods: Two hundred and four patients with newly diagnosed MM who received an autologous stem cell transplantation after induction chemotherapy in our tertiary care center between the years of 2001 and 2018 were evaluated. Results: There were 153 (75%) MM patients who had a glomerular filtration rate (GFR) of ≥60 mL/min and 51 (25%) MM patients who had GFR of <60 mL/min at the time of diagnosis in this study. There was a strong correlation between ISS stage and GFR. The ISS stages were higher in patients who had GFR of <60 mL/min than patients who had GFR of ≥60 mL/min (p<0.001). Patients with GFR of <60 mL/min were significantly more prevalent in the ISS III group than ISS I and II (p<0.001). Conclusion: This study showed that the ISS provides significant prognostic information in MM patients with GFR of ≥60 mL/min at diagnosis. However, in patients with impaired renal function at the time of diagnosis, B2-microglobulin may not be a good prognostic indicator since it may be affected by renal dysfunction as well as tumor burden.
Anahtar Kelime:

Otolog Kök Hücre Transplantasyonuna Uygun Yeni Tanı Konmuş Multipl Myelomlu Hastalarda Glomerüler Filtrasyon Hızına Göre Uluslararası Evreleme Sisteminin Prognostik Öneminin Değerlendirilmesi

Öz:
Amaç: Multipl miyelom (MM) hastalarının prognozu oldukça heterojendir. Bu çalışmanın amacı, hastaların böbrek fonksiyonlarının Uluslararası Evreleme Sistemi’nin (ISS) prognostik performansı üzerindeki etkisini belirlemektir. Ayrıca bu çalışma ile ISS evreli ve böbrek fonksiyonları normal ve anormal olan hastaların ISS evresine göre sağkalım sonuçlarını değerlendirmeyi amaçladık. Gereç ve Yöntemler: 2001-2018 yılları arasında üçüncü basamak merkezimizde indüksiyon kemoterapisi sonrası otolog kök hücre nakli yapılan yeni tanı konmuş MM’li 244 hasta değerlendirildi. Bulgular: Tanı anında glomerüler filtrasyon hızı (GFR) ≥60 mL/dak olan 153 (%75) MM hastası ve GFR’si <60 mL/dak olan 51 (%25) MM hastası vardı. ISS evresi ile GFR arasında güçlü bir ilişki vardı. ISS evreleri, GFR değeri <60 mL/dak olan hastalarda GFR’si ≥60 mL/dak olan hastalara göre daha yüksekti (p<0,001). GFR değeri <60 mL/dak olan hasta sayısı, ISS 3 grubunda ISS 1 ve 2’ye göre anlamlı olarak daha saptandı (p<0,001). Sonuç: Bu çalışma, ISS’nin GFR’si ≥60 mL/dak olan MM hastalarında tanıda önemli prognostik bilgi sağladığını göstermiştir. Bununla birlikte, tanı anında böbrek fonksiyon bozukluğu olan hastalarda B2-mikroglobulin, böbrek fonksiyon bozukluğundan ve tümör yükünden etkilenebileceğinden iyi bir prognostik gösterge olmayabilir.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Dimopoulos MA, Kastritis E, Michalis E, Tsatalas C, Michael M, Pouli A, Kartasis Z, Delimpasi S, Gika D, Zomas A, Roussou M, Konstantopoulos K, Parcharidou A, Zervas K, Terpos E; Greek Myeloma Study Group. The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients’ renal function. Ann Oncol 2011;23:722-729.
  • 2. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-3420.
  • 3. Kastritis E, Zervas K, Symeonidis A, Terpos E, Delimbassi S, Anagnostopoulos N, Michali E, Zomas A, Katodritou E, Gika D, Pouli A, Christoulas D, Roussou M, Kartasis Z, Economopoulos T, Dimopoulos MA. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia 2009;23:1152-1157.
  • 4. Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, Behrens J, Smith A, Child JA, Drayson MT. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002—Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005;23:9219-9226.
  • 5. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016;17:e328-e46.
  • 6. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-470.
  • 7. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1-266.
  • 8. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-656.
  • 9. Ooi MGM, de Mel S, Chng WJ. Risk stratification in multiple myeloma. Curr Hematol Malig Rep 2016;11:137-147.
  • 10. Dimopoulos M, Kastritis E, Rosinol L, Blade J, Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 2008;22:1485- 1493.
  • 11. Eleftherakis-Papaiakovou V, Anagnostopoulos A, Bamias A, Gika D, Symeonidis A, Pouli A, Anagnostopoulos N, Zervas K, Michali E, Kastritis E, Dimopoulos MA. Renal failure in multiple myeloma: incidence, correlations and prognostic significance. Blood 2006;108:5000.
  • 12. Alexanian R, Barlogie B, Dixon D. Renal failure in multiple myeloma. Arch Intern Med 1990;150:1693-1695.
  • 13. Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, Dispenzieri A, Fonseca R, Sher T, Kyle RA, Lin Y, Russell SJ, Kumar S, Bergsagel PL, Zeldenrust SR, Leung N, Drake MT, Kapoor P, Ansell SM, Witzig TE, Lust JA, Dalton RJ, Gertz MA, Stewart AK, Rajkumar SV, Chanan-Khan A, Lacy MQ; Mayo Clinic. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk- Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc 2013;88:360-376.
  • 14. Corso A, Galli M, Mangiacavalli S, Rossini F, Nozza A, Pascutto C, Montefusco V, Baldini L, Cafro AM, Crippa C, Cazzola M, Corradini P. Response-adjusted ISS (RaISS) is a simple and reliable prognostic scoring system for predicting progression-free survival in transplanted patients with multiple myeloma. Am J Hematol 2012;87:150-154.
  • 15. Avet-Loiseau H, Durie BG, Cavo M, Attal M, Gutierrez N, Haessler J, Goldschmidt H, Hajek R, Lee JH, Sezer O, Barlogie B, Crowley J, Fonseca R, Testoni N, Ross F, Rajkumar SV, Sonneveld P, Lahuerta J, Moreau P, Morgan G; International Myeloma Working Group. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia 2013;27:711-717.
  • 16. Park S, Han B, Kim K, Kim SJ, Jang JH, Kim WS, Jung CW. Renal insufficiency in newly-diagnosed multiple myeloma: analysis according to International Myeloma Working Group consensus statement. Anticancer Res 2014;34:4299-4306.
  • 17. Heher EC, Rennke HG, Laubach JP, Richardson PG. Kidney disease and multiple myeloma. Clin J Am Soc Nephrol 2013;8:2007-2017.
  • 18. Goswami C, Poonia S, Sengupta D, Kumar L. Staging system to predict the risk of relapse in multiple myeloma patients undergoing autologous stem cell transplantation. Front Oncol 2019;9:633.
  • 19. Zhang BL, Zhou J, Lin QD, Liu YZ, Zhang YL, Gui RR, Song YP, Fang BJ. Retrospective analysis of the efficacy and influencing factors of autologous hematopoietic stem cell transplantation for multiple myeloma. Artif Organs 2019;43:1028-1034.
  • 20. Pawlyn C, Davies FE. Toward personalized treatment in multiple myeloma based on molecular characteristics. Blood 2019;133:660-675.
  • 21. Shah V, Sherborne AL, Walker BA, Johnson DC, Boyle EM, Ellis S, Begum DB, Proszek PZ, Jones JR, Pawlyn C, Savola S, Jenner MW, Drayson MT, Owen RG, Houlston RS, Cairns DA, Gregory WM, Cook G, Davies FE, Jackson GH, Morgan GJ, Kaiser MF. Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. Leukemia 2018;32:102-110.
  • 22. Boyd KD, Ross FM, Chiecchio L, Dagrada GP, Konn ZJ, Tapper WJ, Walker BA, Wardell CP, Gregory WM, Szubert AJ, Bell SE, Child JA, Jackson GH, Davies FE, Morgan GJ; NCRI Haematology Oncology Studies Group. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia 2012;26:349-355.
APA Çiftçiler R, Göker H, Demiroglu H, HAZNEDAROĞLU İ, Sayınalp N, AKSU S, Özcebe O, BÜYÜKAŞIK Y (2021). Evaluation of Prognostic Significance of the International Staging System According to Glomerular Filtration Rate in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation. , 33 - 40. 10.4274/tjh.galenos.2020.2020.0115
Chicago Çiftçiler Rafiye,Göker Hakan,Demiroglu Haluk,HAZNEDAROĞLU İbrahim Celalettin,Sayınalp Nilgün,AKSU SALIH,Özcebe Osman,BÜYÜKAŞIK Yahya Evaluation of Prognostic Significance of the International Staging System According to Glomerular Filtration Rate in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation. (2021): 33 - 40. 10.4274/tjh.galenos.2020.2020.0115
MLA Çiftçiler Rafiye,Göker Hakan,Demiroglu Haluk,HAZNEDAROĞLU İbrahim Celalettin,Sayınalp Nilgün,AKSU SALIH,Özcebe Osman,BÜYÜKAŞIK Yahya Evaluation of Prognostic Significance of the International Staging System According to Glomerular Filtration Rate in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation. , 2021, ss.33 - 40. 10.4274/tjh.galenos.2020.2020.0115
AMA Çiftçiler R,Göker H,Demiroglu H,HAZNEDAROĞLU İ,Sayınalp N,AKSU S,Özcebe O,BÜYÜKAŞIK Y Evaluation of Prognostic Significance of the International Staging System According to Glomerular Filtration Rate in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation. . 2021; 33 - 40. 10.4274/tjh.galenos.2020.2020.0115
Vancouver Çiftçiler R,Göker H,Demiroglu H,HAZNEDAROĞLU İ,Sayınalp N,AKSU S,Özcebe O,BÜYÜKAŞIK Y Evaluation of Prognostic Significance of the International Staging System According to Glomerular Filtration Rate in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation. . 2021; 33 - 40. 10.4274/tjh.galenos.2020.2020.0115
IEEE Çiftçiler R,Göker H,Demiroglu H,HAZNEDAROĞLU İ,Sayınalp N,AKSU S,Özcebe O,BÜYÜKAŞIK Y "Evaluation of Prognostic Significance of the International Staging System According to Glomerular Filtration Rate in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation." , ss.33 - 40, 2021. 10.4274/tjh.galenos.2020.2020.0115
ISNAD Çiftçiler, Rafiye vd. "Evaluation of Prognostic Significance of the International Staging System According to Glomerular Filtration Rate in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation". (2021), 33-40. https://doi.org/10.4274/tjh.galenos.2020.2020.0115
APA Çiftçiler R, Göker H, Demiroglu H, HAZNEDAROĞLU İ, Sayınalp N, AKSU S, Özcebe O, BÜYÜKAŞIK Y (2021). Evaluation of Prognostic Significance of the International Staging System According to Glomerular Filtration Rate in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation. Turkish Journal of Hematology, 38(1), 33 - 40. 10.4274/tjh.galenos.2020.2020.0115
Chicago Çiftçiler Rafiye,Göker Hakan,Demiroglu Haluk,HAZNEDAROĞLU İbrahim Celalettin,Sayınalp Nilgün,AKSU SALIH,Özcebe Osman,BÜYÜKAŞIK Yahya Evaluation of Prognostic Significance of the International Staging System According to Glomerular Filtration Rate in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation. Turkish Journal of Hematology 38, no.1 (2021): 33 - 40. 10.4274/tjh.galenos.2020.2020.0115
MLA Çiftçiler Rafiye,Göker Hakan,Demiroglu Haluk,HAZNEDAROĞLU İbrahim Celalettin,Sayınalp Nilgün,AKSU SALIH,Özcebe Osman,BÜYÜKAŞIK Yahya Evaluation of Prognostic Significance of the International Staging System According to Glomerular Filtration Rate in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation. Turkish Journal of Hematology, vol.38, no.1, 2021, ss.33 - 40. 10.4274/tjh.galenos.2020.2020.0115
AMA Çiftçiler R,Göker H,Demiroglu H,HAZNEDAROĞLU İ,Sayınalp N,AKSU S,Özcebe O,BÜYÜKAŞIK Y Evaluation of Prognostic Significance of the International Staging System According to Glomerular Filtration Rate in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation. Turkish Journal of Hematology. 2021; 38(1): 33 - 40. 10.4274/tjh.galenos.2020.2020.0115
Vancouver Çiftçiler R,Göker H,Demiroglu H,HAZNEDAROĞLU İ,Sayınalp N,AKSU S,Özcebe O,BÜYÜKAŞIK Y Evaluation of Prognostic Significance of the International Staging System According to Glomerular Filtration Rate in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation. Turkish Journal of Hematology. 2021; 38(1): 33 - 40. 10.4274/tjh.galenos.2020.2020.0115
IEEE Çiftçiler R,Göker H,Demiroglu H,HAZNEDAROĞLU İ,Sayınalp N,AKSU S,Özcebe O,BÜYÜKAŞIK Y "Evaluation of Prognostic Significance of the International Staging System According to Glomerular Filtration Rate in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation." Turkish Journal of Hematology, 38, ss.33 - 40, 2021. 10.4274/tjh.galenos.2020.2020.0115
ISNAD Çiftçiler, Rafiye vd. "Evaluation of Prognostic Significance of the International Staging System According to Glomerular Filtration Rate in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation". Turkish Journal of Hematology 38/1 (2021), 33-40. https://doi.org/10.4274/tjh.galenos.2020.2020.0115